BSE - Delayed Quote INR

Dr. Reddy's Laboratories Limited (DRREDDY.BO)

1,219.85

+13.05

+(1.08%)

At close: 3:29:50 PM GMT+5:30

Dr Reddy's Laboratories Ltd (RDY) Full Year 2025 Earnings Call Highlights: Record Revenue and ...

Dr Reddy's Laboratories Ltd (RDY) reports a milestone year with over $3.8 billion in revenue, while navigating margin pressures and market dynamics.

GuruFocus.com yesterday

RDY
RDY Q4 Earnings Beat Estimates, Generics Revenues Rise Y/Y, Stock Up

Dr. Reddy's stock is up on encouraging fiscal fourth-quarter 2025 results, wherein both earnings and revenues beat estimates, driven by higher global generic sales.

Zacks yesterday

RDY
Dr. Reddy’s Q4 & Full Year FY25 Financial Results

HYDERABAD, India, May 09, 2025--Dr. Reddy’s Laboratories Ltd. today announced its consolidated financial results for the quarter and year ended March 31, 2025.

Business Wire 4 days ago

RDY
India's Dr Reddy's says open to boosting U.S. manufacturing as tariff threat looms

HYDERABAD (Reuters) -India's Dr Reddy's Laboratories, one of country's largest generic drugmakers, said that it is open to expanding its manufacturing footprint in the key U.S. market as tariff threat looms. "We are more than open to work in the United States, to make in the United States when the opportunity comes," CEO Erez Israeli said in a press call on Friday. India's drugmakers that derive significant revenue from North America through their cheaper version of innovator drugs are on tenterhooks about U.S. tariffs on pharma imports.

Reuters 4 days ago

RDY
Dr. Reddy’s Laboratories (RDY): Among the Best Indian Stocks to Buy According to Billionaires

We recently published a list of the 10 Best Indian Stocks to Buy According to Billionaires. In this article, we will take a look at where Dr. Reddy’s Laboratories Limited (NYSE:RDY) stands against other best Indian stocks. India’s stock market had a rough ride during the second half of FY25, amid uncertainty around US tariffs, […]

Insider Monkey 29 days ago

RDY
Bio-Thera and Dr. Reddy's Execute Exclusive Commercialization Agreement for BAT2206, a Proposed Stelara® Biosimilar, and BAT2506, a Proposed Simponi® Biosimilar, for Southeast Asia

Bio-Thera Solutions (688177:SH; "Bio-Thera"), a commercial-stage biopharmaceutical company developing a pipeline of innovative therapies and biosimilars, and Dr. Reddy's Laboratories SA, wholly-owned subsidiary of Dr. Reddy's Laboratories Ltd. (BSE: 500124 | NSE: DRREDDY | NYSE: RDY | NSEIFSC: DRREDDY, along with its subsidiaries hereafter referred to as "Dr. Reddy's"), announce today they have reached commercialization and license agreements for BAT2206, a proposed Stelara® biosimilar, and BAT2

PR Newswire last month

688177.SS

RDY
Alvotech and Dr. Reddy’s Announce FDA Acceptance of Biologic License Application for AVT03, a Proposed Biosimilar to Prolia® and Xgeva®

HYDERABAD, India & REYKJAVIK, Iceland, March 18, 2025--Alvotech and Dr. Reddy’s announce FDA acceptance of Biologic License Application for AVT03, a proposed biosimilar to Prolia® and Xgeva®.

Business Wire last month

ALVO

ALVOW

RDY
Dr. Reddy’s announces recall of Levetiracetam 0.75% Sodium Chloride injection

Dr. Reddy’s (RDY) Laboratories announced that it is recalling one Batch/Lot No: A1540076 of Levetiracetam in 0.75% Sodium Chloride Injection, 1,000 mg/100 mL single-dose infusion bags to the consumer level, in the United States. The product is being recalled because the infusion bag is incorrectly labeled as Levetiracetam in 0.82% Sodium Chloride Injection 500 mg/100 mL single-dose bag, while the aluminum overwrap packaging correctly identifies the product as Levetiracetam in 0.75% Sodium Chlori

TipRanks last month

RDY
Dr. Reddy's Issues a Nationwide Recall of Levetiracetam in 0.75% Sodium Chloride Injection 1,000 mg/100 mL, in the U.S., due to Mislabeling of Infusion Bag

HYDERABAD, India, March 13, 2025--Dr. Reddy's issues a nationwide recall of Levetiracetam in 0.75% Sodium Chloride Injection 1,000 mg/100 mL, due to mislabeling of infusion bag.

Business Wire last month

RDY
Is Dr. Reddy’s Laboratories Limited (RDY) the Best Weight Loss Drug Stock to Buy According to Analysts?

We recently published a list of 10 Best Weight Loss Drug Stocks to Buy According to Analysts. In this article, we are going to take a look at where Dr. Reddy’s Laboratories Limited (NYSE:RDY) stands against other best weight loss drug stocks to buy according to analysts. Global Surge in Obesity Medication Market Driven by […]

Insider Monkey 2 months ago

RDY
Is Dr. Reddy’s Laboratories Limited (RDY) the Best Low Price Pharma Stock to Invest In Right Now?

We recently compiled a list of the 12 Best Low Price Pharma Stocks To Invest In Right Now. In this article, we are going to take a look at where Dr. Reddy’s Laboratories Limited (NYSE:RDY) stands against the other pharma stocks. The Rising Demand for Weight-Loss Medications and GLP-1 Developments Healthcare, which includes numerous businesses that […]

Insider Monkey 2 months ago

RDY
Dr Reddy’s and Shanghai Henlius sign agreement for HLX15

Henlius could earn up to $131.6m, including an upfront payment of $33m.

Pharmaceutical Technology 3 months ago

^YH206

RDY
Dr. Reddy’s enters into collaboration with Henlius for commercialization of HLX15 (daratumumab), a biosimilar candidate to Darzalex® & Darzalex Faspro® in the U.S., and Europe

HYDERABAD, India, February 06, 2025--Dr. Reddy’s Laboratories SA today announced that it has entered into a license agreement with Henlius related to the commercialization of HLX15.

Business Wire 3 months ago

2696.HK

RDY
Henlius and Dr. Reddy's Ink Licensing Deal for HLX15 (investigational daratumumab biosimilar) Expansion in Europe and the U.S.

Shanghai Henlius Biotech, Inc. (2696.HK) today announced it has entered into a license agreement with Dr. Reddy's Laboratories SA, wholly-owned subsidiary of Dr. Reddy's Laboratories Ltd., (BSE: 500124 | NSE: DRREDDY | NYSE: RDY | NSEIFSC: DRREDDY, along with its subsidiaries hereafter referred to as "Dr. Reddy's") for the company's independently developed investigational daratumumab biosimilar HLX15, a recombinant anti-CD38 fully human monoclonal antibody injection. Dr. Reddy's will gain exclus

PR Newswire 3 months ago

RDY

2696.HK
RDY Q3 Earnings Match Estimates, Generics Revenues Rise Y/Y, Stock Down

Dr. Reddy's stock falls on Q3 fiscal 2025 results, wherein earnings match estimates but revenues beat the same.

Zacks 3 months ago

RDY
Dr Reddy's Laboratories Ltd (RDY) Q3 2025 Earnings Call Highlights: Record Revenue Growth ...

Dr Reddy's Laboratories Ltd (RDY) reports a robust 16% YoY revenue growth, driven by strategic product launches and market expansions, despite facing price erosion and compliance challenges.

GuruFocus.com 3 months ago

RDY
Indian drugmaker Dr Reddy's shares slide after Q3 profit miss

The generic drugmaker was the top loser on the Nifty Pharma index and the benchmark Nifty 50 index. "The drop in shares comes as market sees near-term concerns over the company's muted U.S. sales," said Sumit Gupta, analyst at Centrum Broking. Indian generic drugmakers are struggling with slower sales in the United States, delayed approvals for new drug applications and lower pricing amid stiff competition.

Reuters 3 months ago

RDY
Dr Reddy's Laboratories Q3 Earnings: Double-Digit Growth Aided By Newly Acquired Nicotine Replacement Business

On Thursday, Dr. Reddy's Laboratories Ltd (NYSE:RDY) stock is trading lower after the company released third-quarter 2025 earnings. The pharma company clocked a net income of $165 million, marginally up from $161 million a year ago. Revenue increased from $843 million to $977 million — almost a 16% jump. The growth was largely driven by revenues from the recently acquired Nicotine Replacement Therapy (NRT) portfolio, as well as revenues from India and Emerging Markets. Last year, Haleon plc (NYS

Benzinga 3 months ago

RDY
Dr. Reddy’s Q3 & 9MFY25 Financial Results

HYDERABAD, India, January 23, 2025--Dr. Reddy’s Laboratories Ltd. today announced its consolidated financial results for the quarter and nine months ended December 31, 2024.

Business Wire 3 months ago

RDY
Indian drugmaker Dr Reddy's says it is 'optimistic' about Trump administration

BENGALURU/HYDERABAD (Reuters) -Indian generic drugmaker Dr Reddy's Laboratories on Thursday said it was optimistic about the Donald Trump administration, as it believes the country would have an edge amid tensions between the United States and China. "I believe that the type of products that we bring in and the positioning of India is favorable," CEO Erez Israeli said in a press call, adding that the company's drugs in the U.S. market are cheaper than the current alternatives. Earlier in the day, the generic drugmaker reported consolidated net profit of 14.14 billion rupees ($163.7 million) for the quarter ended Dec. 31, missing analysts' estimate of 14.89 billion rupees as per data compiled by LSEG.

Reuters 3 months ago

RDY

Performance Overview

Return	DRREDDY.BO	S&P BSE SENSEX (^BSESN)
YTD	-12.13%	+4.08%
1-Year	+7.04%	+11.25%
3-Year	+72.51%	+54.05%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Dr. Reddy's Laboratories Limited (DRREDDY.BO)

Dr Reddy's Laboratories Ltd (RDY) Full Year 2025 Earnings Call Highlights: Record Revenue and ...

RDY Q4 Earnings Beat Estimates, Generics Revenues Rise Y/Y, Stock Up

Dr. Reddy’s Q4 & Full Year FY25 Financial Results

India's Dr Reddy's says open to boosting U.S. manufacturing as tariff threat looms

Dr. Reddy’s Laboratories (RDY): Among the Best Indian Stocks to Buy According to Billionaires

Bio-Thera and Dr. Reddy's Execute Exclusive Commercialization Agreement for BAT2206, a Proposed Stelara® Biosimilar, and BAT2506, a Proposed Simponi® Biosimilar, for Southeast Asia

Alvotech and Dr. Reddy’s Announce FDA Acceptance of Biologic License Application for AVT03, a Proposed Biosimilar to Prolia® and Xgeva®

Dr. Reddy’s announces recall of Levetiracetam 0.75% Sodium Chloride injection

Dr. Reddy's Issues a Nationwide Recall of Levetiracetam in 0.75% Sodium Chloride Injection 1,000 mg/100 mL, in the U.S., due to Mislabeling of Infusion Bag

Is Dr. Reddy’s Laboratories Limited (RDY) the Best Weight Loss Drug Stock to Buy According to Analysts?

Is Dr. Reddy’s Laboratories Limited (RDY) the Best Low Price Pharma Stock to Invest In Right Now?

Dr Reddy’s and Shanghai Henlius sign agreement for HLX15

Dr. Reddy’s enters into collaboration with Henlius for commercialization of HLX15 (daratumumab), a biosimilar candidate to Darzalex® & Darzalex Faspro® in the U.S., and Europe

Henlius and Dr. Reddy's Ink Licensing Deal for HLX15 (investigational daratumumab biosimilar) Expansion in Europe and the U.S.

RDY Q3 Earnings Match Estimates, Generics Revenues Rise Y/Y, Stock Down

Dr Reddy's Laboratories Ltd (RDY) Q3 2025 Earnings Call Highlights: Record Revenue Growth ...

Indian drugmaker Dr Reddy's shares slide after Q3 profit miss

Dr Reddy's Laboratories Q3 Earnings: Double-Digit Growth Aided By Newly Acquired Nicotine Replacement Business

Dr. Reddy’s Q3 & 9MFY25 Financial Results

Indian drugmaker Dr Reddy's says it is 'optimistic' about Trump administration

Performance Overview